ðɪs ɪŋklˈuːdz nˈuːmɚɹəs pˈæʔn̩t lˌɪɾɪɡˈeɪʃən kˈeɪsᵻz ɪn ˈɪzɹiːəl, ɹᵻɡˈɑːɹdɪŋ ɐ wˈaɪd ɚɹˈeɪ ʌv dʒənˈɛɹɪk vˈɜːʒənz ʌv vˈɛɹiəs dɹˈʌɡz ɪn pɚtˈɪkjʊlɚ, blˈɑːkbʌstɚ dɹˈʌɡz, ˈiːtʃ hˌævɪŋ ˈænjuːəl sˈeɪlz ɪn ɛksˈɛs ʌv dˈɑːlɚ wˈʌn bˈɪliən, æz wˈɛl æz kˈeɪsᵻz ɹᵻlˈeɪɾɪŋ tə tˈɛvəz ˈɪnəvˌeɪɾɪv pɹˈɑːdʌkts.
This includes numerous patent litigation cases in Israel, regarding a wide array of generic versions of various drugs (in particular, blockbuster drugs, each having annual sales in excess of $1 billion), as well as cases relating to Teva’s innovative products.